# ADNIMERGE Usage Summary Report

**Generated:** December 25, 2025  
**Report Type:** Data Utilization Analysis

---

## EXECUTIVE SUMMARY: How Much ADNIMERGE Have We Used?

### Quick Answer:
**We have used approximately 0.5-1% of the ADNIMERGE data** (by subject count), but we've extracted what we need for current experiments.

---

## üìä ADNIMERGE FILE DETAILS

### File Information:
- **Location:** `D:\discs\ADNI\ADNIMERGE_23Dec2025.csv`
- **File Size:** 13.26 MB (13,259,788 bytes)
- **Format:** CSV with extensive clinical and cognitive data
- **Last Updated:** December 23, 2025

### What ADNIMERGE Contains:
The ADNIMERGE file is a comprehensive longitudinal dataset containing:
- **Subjects:** Thousands of ADNI participants (complete cohort across ADNI-1, ADNI-2, ADNI-GO, ADNI-3)
- **Columns:** 200+ clinical, cognitive, biomarker, and demographic variables
- **Timepoints:** Multiple visits per subject (baseline, m06, m12, m24, etc.)
- **Variables Include:**
  - Demographics: Age, Sex, Education (PTEDUCAT)
  - Cognitive: MMSE, ADAS, CDR, CDRSB
  - Biomarkers: CSF (ABETA, TAU, PTAU), APOE4 genotype
  - Imaging: Volumes, thickness measures
  - Diagnoses: DX (CN, MCI, Dementia)
  - Vascular: Blood pressure, medical history

---

## üî¢ WHAT WE HAVE IN OUR PROJECT

### 1. MRI Data (Physical Scans)
- **Location:** `D:\discs\ADNI\` folder
- **NIfTI Files:** 230 brain scans
- **Unique Subjects:** 203
- **Scan Period:** 2005-2008 (ADNI-1 baseline and early follow-ups)
- **File Type:** `.nii` (3D structural MRI volumes)
- **Processing Types:**
  - MPR GradWarp B1 N3 Scaled: 125 scans (54%)
  - MPR-R: 50 scans (22%)
  - MPR N3 Scaled: 35 scans (15%)
  - Other: 20 scans (9%)

### 2. Extracted Features
- **Location:** `D:\discs\extracted_features\adni_features.csv`
- **File Size:** 7.10 MB
- **Total Rows:** 1,325 feature vectors
- **Unique Subjects:** ~203 (multiple scans per subject)
- **Feature Columns:** 519
  - 512 ResNet18 MRI features (f0...f511)
  - subject_id
  - scan_path
  - Additional metadata columns

### 3. Clinical Data Used from ADNIMERGE
Based on `DATA_CLEANING_AND_PREPROCESSING.md`, we've merged:
- **Education (PTEDUCAT):** For Level-1 and Level-2 experiments
- **MMSE:** For Level-2 (circular detection)
- **CDR-SB:** For Level-2 (circular detection) 
- **Age:** Extracted from EXAMDATE and DOB
- **Diagnosis (DX):** For labeling subjects as CN, MCI, Dementia

### 4. What We've Used in Training
From the research paper and documentation:

**ADNI Level-1 (Honest Early Detection):**
- **Subjects Used:** 629 total (503 train, 126 test)
- **Features:** MRI (512) + Age + Education (or Age + Sex)
- **From ADNIMERGE:** Age, Education, DX label
- **Performance:** AUC ~0.58-0.60

**ADNI Level-2 (Circular with Cognitive Scores):**
- **Subjects Used:** Subset of 629 (those with complete data)
- **Features:** MRI + MMSE + CDRSB + Age + APOE4 + Education
- **From ADNIMERGE:** MMSE, CDRSB, Age, Education, APOE4 (if available), DX
- **Performance:** AUC ~0.99 (circular, as expected)

---

## üìà USAGE BREAKDOWN

### By Subject Count:

```
ADNIMERGE Total Subjects: ~15,000+ (estimated, full ADNI cohort)
Our MRI Files: 203 subjects
Subjects Used in Training: 629 rows ‚Üí ~200-300 unique subjects
                            (multiple timepoints per subject)

Usage Percentage: 203 / 15,000 = ~1.4% of subjects
                  OR
                  629 / (total ADNIMERGE rows) = ~0.5-2%
```

### By Variables (Columns):

```
ADNIMERGE Total Columns: 200+
Columns We've Used: ~6-8

Used Variables:
‚úì PTID (subject ID for matching)
‚úì DX (diagnosis label)
‚úì PTEDUCAT (education)
‚úì MMSE (Level-2 only)
‚úì CDRSB (Level-2 only)
‚úì EXAMDATE (for age calculation)
? APOE4 (mentioned in Level-2, may not be fully utilized)

Unused but Available:
‚úó CSF biomarkers (ABETA, TAU, PTAU)
‚úó Vascular risk factors
‚úó Detailed neuropsych battery
‚úó Genetic data beyond APOE4
‚úó Longitudinal progression data
‚úó MRI volumetrics from ADNIMERGE
‚úó PET imaging variables
‚úó Many more...

Usage Percentage by Columns: 6-8 / 200+ = ~3-4%
```

### By Timepoints:

```
ADNIMERGE Timepoints: Baseline, m03, m06, m12, m18, m24, m36, m48...
Our Usage: Primarily baseline (bl) visits only

Usage Percentage: ~10-20% of longitudinal data
```

---

## üéØ WHAT WE'VE EXTRACTED VS WHAT'S AVAILABLE

### Currently Extracted:
‚úÖ **Demographics:**
   - Age (calculated from DOB + EXAMDATE)
   - Education (PTEDUCAT)
   - Sex (if used in Level-1)

‚úÖ **Cognitive Scores (Level-2 only):**
   - MMSE
   - CDR-SB

‚úÖ **Diagnosis Labels:**
   - DX (CN, EMCI, LMCI, AD)

‚úÖ **MRI Features:**
   - 512-dim ResNet18 features from our scans (NOT from ADNIMERGE)
   - ADNIMERGE has volumetric measures we haven't used

### Available But NOT YET Used:

‚ö†Ô∏è **Biomarkers (HIGH VALUE for improving fusion):**
   - CSF AŒ≤42 (ABETA)
   - CSF Total Tau (TAU)
   - CSF Phospho-Tau (PTAU)
   - **Coverage:** ~40-60% of subjects have CSF data

‚ö†Ô∏è **Genetic Data:**
   - APOE4 allele count (0, 1, or 2)
   - **Coverage:** ~80-90% of subjects

‚ö†Ô∏è **Vascular Risk Factors:**
   - Hypertension
   - Diabetes
   - Cardiovascular history
   - BMI

‚ö†Ô∏è **Extended Neuropsych:**
   - ADAS-Cog scores
   - Logical Memory
   - Category Fluency
   - Trail Making Test
   - And many more...

‚ö†Ô∏è **Longitudinal Data:**
   - We have baseline only
   - Could use follow-up visits for progression prediction
   - Conversion prediction (CN‚ÜíMCI‚ÜíAD)

‚ö†Ô∏è **Imaging Derivatives in ADNIMERGE:**
   - Hippocampal volume
   - Entorhinal cortical thickness
   - Whole brain volume
   - Ventricular volume
   - (We extract our own MRI features instead)

---

## üí° IMPLICATIONS FOR YOUR PROJECT

### Current Status:
1. **MRI Data:** ‚úÖ Fully extracted (230 scans ‚Üí 1,325 feature vectors)
2. **Basic Clinical:** ‚úÖ Used (Age, Education, DX labels)
3. **Cognitive Scores:** ‚úÖ Used in Level-2 (MMSE, CDRSB)
4. **Advanced Biomarkers:** ‚ùå NOT used yet (CSF, APOE4, vascular)

### Why Fusion Models Aren't Working:
As documented in `PROJECT_ASSESSMENT_HONEST_TAKE.md`:
- Using **only 2-3 clinical features** (Age, Education, Sex)
- These are **weak correlates**, not disease biomarkers
- **512 MRI features + 2 demographic features = feature quality mismatch**
- Result: Fusion adds noise, not signal

### Path Forward (from REALISTIC_PATH_TO_PUBLICATION.md):
**To improve fusion performance, you should extract:**

**Level-1.5 (Biomarker-Enhanced, Still Honest):**
```python
Features = [
    MRI (512 dims),           # Already have
    CSF_ABETA,                # Need to extract from ADNIMERGE
    CSF_TAU,                  # Need to extract from ADNIMERGE  
    CSF_PTAU,                 # Need to extract from ADNIMERGE
    APOE4,                    # Need to extract from ADNIMERGE
    Age,                      # Already have
    Education                 # Already have
]
Total: 518 features (512 MRI + 6 clinical)
```

**Expected Improvement:**
- Current Level-1: AUC ~0.58-0.60 (Age + Education only)
- With Biomarkers (Level-1.5): AUC ~0.70-0.75 (estimated)
- Fusion gain: +5-8% (vs current +1.5%)

---

## üìã SUMMARY TABLE

| **Aspect** | **Available in ADNIMERGE** | **Currently Used** | **Usage %** |
|------------|---------------------------|-------------------|-------------|
| **Subjects** | ~15,000+ | 203 (MRI) / 629 (training rows) | ~1-4% |
| **Variables** | 200+ | 6-8 | ~3-4% |
| **Timepoints** | Baseline + 10+ follow-ups | Baseline only | ~10% |
| **Cognitive Scores** | 15+ tests | 2 (MMSE, CDRSB for Level-2) | ~13% |
| **Biomarkers** | CSF, genetics, imaging | None (CSF/genetics not extracted) | 0% |
| **Data Size** | 13.26 MB (ADNIMERGE csv) | ~200KB (extracted columns) | ~1.5% |

---

## üöÄ ACTIONABLE RECOMMENDATIONS

### To Use More of ADNIMERGE (Priority Order):

**1. Extract CSF Biomarkers (HIGH PRIORITY - 2-3 days)**
```python
columns_to_extract = ['PTID', 'VISCODE', 'ABETA', 'TAU', 'PTAU']
# This will improve Level-1.5 performance significantly
```

**2. Extract APOE4 (MEDIUM PRIORITY - 1 day)**
```python
columns_to_extract = ['PTID', 'APOE4']
# Strong genetic risk factor
```

**3. Extract Vascular Risk (LOW-MEDIUM PRIORITY - 2 days)**
```python
# Check for: hypertension, diabetes, BMI, smoking
# May improve clinical feature quality
```

**4. Longitudinal Analysis (OPTIONAL - 1-2 weeks)**
```python
# Use m06, m12, m24 timepoints
# Predict conversion rather than cross-sectional detection
# Requires restructuring the entire analysis
```

**5. Extended Neuropsych Scores (NOT RECOMMENDED)**
```python
# Would be circular like MMSE/CDRSB
# Defeats "early detection" purpose
```

---

## üî¨ RESEARCH PERSPECTIVE

### What You've Done:
- ‚úÖ Extracted baseline demographics (Age, Education)
- ‚úÖ Matched subjects to MRI scans
- ‚úÖ Created train/test splits with proper labels
- ‚úÖ Used minimal circular features for honest evaluation

### What's Left in ADNIMERGE:
- üìä **Biomarker treasure trove** (CSF, APOE4) for Level-1.5
- üìà **Longitudinal progression data** for conversion prediction
- üß¨ **Genetic and vascular data** for comprehensive modeling
- üß† **Imaging-derived measures** (volumes, thickness) from FreeSurfer
- üìã **Extensive neuropsych** (circular but useful for upper-bound)

### Bottom Line:
**You've used ~1-5% of ADNIMERGE by various metrics, which is appropriate for your current research focus on honest cross-sectional detection. The remaining 95-99% contains:**
1. Biomarkers that could fix your fusion models (CSF, APOE4)
2. Longitudinal data for different research questions (progression, conversion)
3. Additional subjects from later ADNI phases (ADNI-2, ADNI-3)
4. Many variables you don't need for your current scope

**Next Step:** Extract CSF + APOE4 to create Level-1.5 and see if fusion finally works!

---

## üìù FILES TO CHECK FOR DETAILS

1. **Feature Extraction:** `d:\discs\extracted_features\adni_features.csv`
2. **Training Data:** `d:\discs\project_adni\data\csv\` (train/test CSVs)
3. **MRI Scans:** `d:\discs\ADNI\` (203 subject folders, 230 .nii files)
4. **Clinical Source:** `d:\discs\ADNI\ADNIMERGE_23Dec2025.csv` (13.26 MB)
5. **Usage Doc:** `d:\discs\DATA_CLEANING_AND_PREPROCESSING.md` (lines 257, 275, 562-564)
6. **Analysis:** `d:\discs\PROJECT_ASSESSMENT_HONEST_TAKE.md` (explains why current features are weak)
7. **Action Plan:** `d:\discs\REALISTIC_PATH_TO_PUBLICATION.md` (how to extract biomarkers)

---

## END OF REPORT

**TL;DR:** You've used **~1-5% of ADNIMERGE** (203 subjects out of 15K+, and 6-8 columns out of 200+). This is fine for your current experiments, but the **unused 95%** contains CSF biomarkers and APOE4 that could dramatically improve your fusion models. Extract those next if you want competitive results!
